Dual procedure combines liver transplant, bariatric surgery - Middle East Business News and Information
Dubai, United Arab Emirates— Mayo Clinic surgeons have found that an innovative approach can help patients with obesity get lifesaving care. Obesity can be a barrier to liver transplant . Julie Heimbach, M.D. , director of the Mayo Clinic Transplant Center in Rochester, Minnesota, says that combining gastric sleeve surgery, a type of bariatric surgery , with liver transplantation is effective in addressing both health issues.
This dual procedure is especially helpful for patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease . MASLD happens when fat builds up in the liver, often without symptoms. It's mostly caused by obesity — defined as a body mass index (BMI) of 30 or higher. In advanced stages, MASLD can lead to serious liver damage that requires a transplant.
'Metabolic-associated steatotic liver disease is the most common liver disease, not only in the United States but worldwide,' Dr. Heimbach says.
As obesity rates rise, so does the need to treat patients with MASLD.
'When we have excess fat that builds up in the liver, this can lead to inflammation and scarring and even advanced liver disease,' she says.
It won't cause complications for everyone, but, for some, it can progress to cirrhosis , severe scarring of the liver.
'When a patient develops cirrhosis, they can then need a liver transplant,' Dr. Heimbach says.
And having extra weight can be a reason patients might not be eligible for transplant. At Mayo Clinic, the approach is to help patients with obesity as well as transplant.
'We consider both liver transplant and what's called a sleeve gastrectomy, which is a type of weight-loss operation that can be used as a tool to help patients be successful in managing not only their liver disease with a liver transplant, but their obesity with the sleeve gastrectomy,' Dr. Heimbach explains.
The procedures are done simultaneously with multiple teams working together. Dr. Heimbach says it's about providing patients the care they need.
'I'm excited about what transplant offers to all of our patients, which is to be able to return to the life that they had before they got sick. And for patients who were carrying extra weight, not only are they healthy again, but now they're able to really fully enjoy and be fully participating in their life,' she says.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
08-07-2025
- Mid East Info
Mayo Clinic researchers link inherited mutation to fatty liver disease - Middle East Business News and Information
Dubai, United Arab Emirates; July, 2025 — Researchers at Mayo Clinic's Center for Individualized Medicine have discovered a rare genetic variant that can directly cause metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease. Until now, scientists believed the disease resulted from a combination of genetic and environmental factors. This study, published in Hepatology, reveals that in some cases, a single inherited variant can be the primary driver. The researchers identified this variant in the MET gene, which regulates liver repair and fat metabolism. When the gene malfunctions, fat accumulates in liver cells and triggers inflammation. Over time, this leads to fibrosis and scarring, which stiffens the liver. In severe cases, the disease progresses to cirrhosis, resulting in irreversible liver damage or liver cancer. Metabolic dysfunction-associated steatotic liver disease affects about one-third of adults worldwide. Its advanced form, metabolic dysfunction-associated steatohepatitis, is expected to become the leading cause of cirrhosis and the reason for liver transplants in the coming years. 'This discovery opens a window into how rare inherited genetic variants can drive common diseases,' says lead author Filippo Pinto e Vairo, M.D, Ph.D., medical director of the Program for Rare and Undiagnosed Diseases at Mayo Clinic's Center for Individualized Medicine. 'It provides new insights into this disease pathogenesis and potential therapeutic targets for future research.' The discovery emerged from the genomic data of a woman and her father with metabolic dysfunction-associated steatohepatitis. They had no history of diabetes or high cholesterol, two common risk factors for fat buildup in the liver. With no clear explanation, researchers examined the DNA from more than 20,000 genes to find answers. They found a small but potentially significant error in the MET gene. In collaboration with the Medical College of Wisconsin's John & Linda Mellowes Center for Genomic Sciences and Precision Medicine, led by Raul Urrutia, M.D., the scientists determined that the mutation disrupted a critical biological process. Genes are made up of chemical letters that provide instructions for the body's functions. In this case, a single swapped letter — among thousands — scrambled the message, preventing the liver from properly processing fat. This rare variant, found in the family, has not been reported in existing literature or public databases. 'This study demonstrates that rare diseases are not rare but often hidden in the large pool of complex disorders, underscoring the immense power of individualized medicine in identifying them, and enabling the design of advanced diagnostics and targeted therapies,' Dr. Urrutia says. To explore the variant's broader impact, researchers turned to Mayo Clinic's Tapestry study, a large-scale exome sequencing effort aimed at uncovering genomic drivers of disease. The Tapestry study analyzed germline DNA from over 100,000 participants across the U.S., creating a comprehensive genomic data repository that supports research into both well-known and emerging health conditions. Among nearly 4,000 adult Tapestry participants with metabolic dysfunction-associated steatotic liver disease, about 1% carried rare, potentially causative variants in the same MET gene. Of these, nearly 18% had variants in the same critical region as the initial woman and her father, further supporting its role in liver disease. 'This finding could potentially affect hundreds of thousands, if not millions, of people worldwide with or at risk for metabolic dysfunction-associated steatotic liver disease,' says Konstantinos Lazaridis, M.D., a lead author and the Carlson and Nelson Endowed Executive Director for the Center for Individualized Medicine. Dr. Lazaridis emphasized the significance of this discovery as it relates to the Tapestry study's impactful contributions. 'Once a pathogenic variant is discovered, interrogating our Tapestry data repository is giving us a clearer lens into the hidden layers of disease, and this discovery is one of the first to demonstrate its scientific significance,' Dr. Lazaridis says. 'This finding highlights the profound value of studying familial diseases and the merit of large-scale genomic datasets, which can reveal rare genetic variations with broader implications for population health.' This discovery also reflects the importance of integrating genomics into clinical care at Mayo Clinic, where teams use advanced technologies to help solve complex medical mysteries. Since its launch in 2019, the Program for Rare and Undiagnosed Diseases has helped more than 3,200 patients with complex and serious conditions gain access to comprehensive genomic testing. It collaborates with nearly 300 clinicians from 14 divisions across the enterprise to bring precision diagnostics to patients with rare conditions, including rare liver diseases. Future studies will explore how this genomic discovery in metabolic dysfunction-associated steatotic liver disease can inform targeted treatments and improve disease management.
Mid East Info
01-07-2025
- Mid East Info
Mayo Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancer
Dubai, United Arab Emirates; June, 2025 — A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation — KRAS circulating tumor DNA ctDNA— strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma (PDAC). The mutation was identified using a readily available and clinically approved blood and abdominal fluid test. PDAC is an aggressive form of cancer that is often difficult to diagnose. Most patients already have cancer spread to other parts of their body when initially diagnosed, and current tests often miss this hidden spread. This makes it challenging to determine the best treatment strategy. The findings, published in the Annals of Surgical Oncology, may help identify patients who are more likely to have cancer spread to other parts of the body, therefore providing doctors and patients with the right information to make informed decisions about treatment. 'This is a major advancement for pancreatic ductal adenocarcinoma,' says Mark Truty, M.D., hepatobiliary and pancreatic surgical oncologist within Mayo Clinic's Department of Surgery. Dr. Truty is senior author of the study. 'We've had this genetic testing available for a number of years, however, we did not know the significance of the results or how to interpret them. Having the KRAS status will allow the patient and their provider to make better decisions about their individual cancer treatment.' The prospective cohort study, involving nearly 800 patients — the largest patient series to date in the literature using ctDNA — found that 20%-30% of patients with PDAC have detectable mutant KRAS ctDNA in the blood and/or peritoneum, and that those without any previous treatment, such as chemotherapy, had the highest incidence. Thus, the study suggests that ctDNA assays should be performed prior to treatment to have the highest yield. The researchers examined data between 2018 and 2022. Blood sample tests revealed that 104 patients (14%) had KRAS ctDNA mutation. These patients were more likely to develop advanced, spreading cancer and had a lower survival rate. Further testing of fluid from around the abdominal cavity in 419 patients showed similar results: 123 (29%) had the marker, and these patients also experienced worse outcomes. The presence of this marker, whether in blood or abdominal fluid, indicated a poorer prognosis. The study highlights that while surgery is the only known cure, most patients experience cancer spread after surgery. The test helps identify patients less likely to benefit from surgery alone, guiding treatment decisions towards chemotherapy and/or radiation before surgery. For patients without the KRAS mutation (approximately 10% of cases), the test is less conclusive and other tests are needed. 'Historically, we've known that KRAS mutations are associated with a more biologically aggressive pancreatic cancer,' says Jennifer Leiting, M.D., hepatobiliary and pancreatic surgeon within Mayo Clinic's Department of Surgery. Dr. Leiting is first author of the study. 'But this large study gives us a much clearer understanding of how to interpret the test results and use them to improve patient care. It allows for more accurate staging at diagnosis, leading to better treatment decisions.' The researchers suggest that this test should become a standard part of the initial diagnosis for PDAC, enabling more personalized risk stratification and effective treatment plans. 'This improved diagnostic capability offers hope for patients and their families facing this challenging disease,' says Dr. Truty. 'It's optimistic to see how advances in genetic testing are directly helping our patients.'
Mid East Info
26-06-2025
- Mid East Info
Mayo Clinic uncovers brain cell changes that could explain Tourette syndrome - Middle East Business News and Information
Dubai, United Arab Emirates; June , 2025 — A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition. This deficit may be a key reason why their motor signals go unchecked, leading to the involuntary tics that define the disorder. The study, published in Biological Psychiatry, is the first to analyze individual brain cells from people with Tourette disorder. The findings also shed light on how different types of brain cells may interact in ways that contribute to the syndrome's symptoms. 'This research may help lay the foundation for a new generation of treatments,' says Alexej Abyzov, Ph.D., a genomic scientist in Mayo Clinic's Center for Individualized Medicine and a co-author of the study. 'If we can understand how these brain cells are altered and how they interact, we may be able to intervene earlier and more precisely.' Tourette disorder is a neurodevelopmental condition that typically begins in childhood. It causes repeated, involuntary movements and vocalizations such as eye blinking, throat clearing or facial grimacing. While genetic studies have identified some risk genes, the biological mechanisms behind the condition have remained unclear. To better understand what's happening in the brain with Tourette syndrome, Dr. Abyzov and his team analyzed more than 43,000 individual cells from postmortem brain tissue of people with and without the condition. They focused on the basal ganglia, a region of the brain that helps control movement and behavior. In each cell, they looked at how genes were working. They also analyzed how changes in the brain's gene-control systems might trigger stress and inflammation. First, they found in people with Tourette syndrome a 50% reduction in interneurons, which are brain cells that help calm excess signals in the brain's movement circuits. They also observed stress responses in two other brain cell types. Medium spiny neurons, which make up most of the cells in basal ganglia and help send movement signals, showed reduced energy production. Microglia, the brain's immune cells, showed inflammation. The two responses were closely linked, suggesting the cells may be interacting in Tourette disorder. 'We're seeing different types of brain cells reacting to stress and possibly communicating with each other in ways that could be driving symptoms,' says Yifan Wang, Ph.D., co-author of the study. The study also provides evidence that the underlying cause of brain cell changes in Tourette disorder may be linked to parts of DNA that control when genes turn on and off. 'Tourette patients seem to have the same functional genes as everyone else but the coordination between them is broken,' Dr. Abyzov says. Next, the researchers plan to study how these brain changes develop over time and look for genetic factors that may help explain the disorder. The study was conducted in collaboration with the lab of Flora M. Vaccarino, M.D., at Yale University. For a complete list of authors, disclosures and funding, review the study.
